Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.25
NUVA's Cash-to-Debt is ranked lower than
85% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. NUVA: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
NUVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 1.01 Max: No Debt
Current: 0.25
Equity-to-Asset 0.44
NUVA's Equity-to-Asset is ranked lower than
74% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NUVA: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
NUVA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.16  Med: 0.49 Max: 0.9
Current: 0.44
-0.16
0.9
Interest Coverage 3.05
NUVA's Interest Coverage is ranked lower than
90% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. NUVA: 3.05 )
Ranked among companies with meaningful Interest Coverage only.
NUVA' s Interest Coverage Range Over the Past 10 Years
Min: 0.65  Med: 2.32 Max: No Debt
Current: 3.05
Piotroski F-Score: 4
Altman Z-Score: 3.60
Beneish M-Score: -2.45
WACC vs ROIC
9.39%
5.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 12.84
NUVA's Operating Margin % is ranked higher than
76% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NUVA: 12.84 )
Ranked among companies with meaningful Operating Margin % only.
NUVA' s Operating Margin % Range Over the Past 10 Years
Min: -15.73  Med: 3.95 Max: 17.15
Current: 12.84
-15.73
17.15
Net Margin % 3.29
NUVA's Net Margin % is ranked higher than
56% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. NUVA: 3.29 )
Ranked among companies with meaningful Net Margin % only.
NUVA' s Net Margin % Range Over the Past 10 Years
Min: -12.92  Med: 0.83 Max: 16.37
Current: 3.29
-12.92
16.37
ROE % 4.56
NUVA's ROE % is ranked higher than
57% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. NUVA: 4.56 )
Ranked among companies with meaningful ROE % only.
NUVA' s ROE % Range Over the Past 10 Years
Min: -15.05  Med: 1 Max: 21.43
Current: 4.56
-15.05
21.43
ROA % 2.06
NUVA's ROA % is ranked higher than
57% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. NUVA: 2.06 )
Ranked among companies with meaningful ROA % only.
NUVA' s ROA % Range Over the Past 10 Years
Min: -7.72  Med: 0.47 Max: 10.76
Current: 2.06
-7.72
10.76
ROC (Joel Greenblatt) % 25.90
NUVA's ROC (Joel Greenblatt) % is ranked higher than
75% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. NUVA: 25.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NUVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -42.62  Med: 10.28 Max: 47.3
Current: 25.9
-42.62
47.3
3-Year Revenue Growth Rate 6.70
NUVA's 3-Year Revenue Growth Rate is ranked higher than
62% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. NUVA: 6.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NUVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40.2  Med: 12.55 Max: 480.7
Current: 6.7
-40.2
480.7
3-Year EBITDA Growth Rate 21.60
NUVA's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. NUVA: 21.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NUVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -36.3 Max: 24.4
Current: 21.6
0
24.4
3-Year EPS without NRI Growth Rate 59.50
NUVA's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NUVA: 59.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NUVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.3  Med: -30.4 Max: 162.1
Current: 59.5
-66.3
162.1
GuruFocus has detected 4 Warning Signs with NuVasive Inc $NUVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NUVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NUVA Guru Trades in Q1 2016

Pioneer Investments 33,834 sh (New)
Paul Tudor Jones 21,787 sh (New)
Steven Cohen 674,900 sh (+206.91%)
RS Investment Management 1,031,723 sh (+36.98%)
Mario Gabelli 170,000 sh (+2.32%)
Ken Fisher 1,410,780 sh (+0.51%)
PRIMECAP Management 901,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 806,000 sh (unchged)
Joel Greenblatt Sold Out
John Paulson Sold Out
Jim Simons 260,200 sh (-9.21%)
» More
Q2 2016

NUVA Guru Trades in Q2 2016

Pioneer Investments 63,589 sh (+87.94%)
Jim Simons 319,188 sh (+22.67%)
Ken Fisher 1,412,861 sh (+0.15%)
Mario Gabelli 167,000 sh (-1.76%)
PRIMECAP Management 869,600 sh (-3.49%)
RS Investment Management 784,483 sh (-23.96%)
Steven Cohen 242,400 sh (-64.08%)
Paul Tudor Jones 3,712 sh (-82.96%)
Eaton Vance Worldwide Health Sciences Fund 344,200 sh (-57.30%)
» More
Q3 2016

NUVA Guru Trades in Q3 2016

Jana Partners 80,744 sh (New)
Paul Tudor Jones 5,600 sh (+50.86%)
Pioneer Investments 70,786 sh (+11.32%)
Ken Fisher 1,422,585 sh (+0.69%)
Steven Cohen Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
PRIMECAP Management 869,000 sh (-0.07%)
Mario Gabelli 165,000 sh (-1.20%)
Jim Simons 129,600 sh (-59.40%)
» More
Q4 2016

NUVA Guru Trades in Q4 2016

Andreas Halvorsen 695,707 sh (New)
Jana Partners 1,810,169 sh (+2141.86%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Mario Gabelli 162,500 sh (-1.52%)
Ken Fisher 1,398,259 sh (-1.71%)
PRIMECAP Management 853,900 sh (-1.74%)
Pioneer Investments 31,754 sh (-55.14%)
» More
» Details

Insider Trades

Latest Guru Trades with NUVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:MASI, OTCPK:FSPKF, OTCPK:EKTAY, NAS:IART, OTCPK:GGNDF, NAS:WMGI, NYSE:NVRO, NYSE:GMED, NYSE:PEN, NAS:ABMD, NAS:LIVN, NAS:ZLTQ, OTCPK:CNVVY, OTCPK:NHNKY, OTCPK:CHEOY, OTCPK:SDMHF, NAS:CYNO, NAS:INGN, OTCPK:IOBCF, NAS:BABY » details
Traded in other countries:NK8.Germany,
NuVasive Inc is a medical device company. The Company develops minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its currently-marketed product portfolio is focused on applications for spine fusion surgery.

NuVasive Inc was incorporated in Delaware on July 21, 1997, and began commercializing its products in 2001. It is a medical device company engaged in developing minimally disruptive surgical products and procedures for the spine. The Company's current-marketed product portfolio is engaged in applications for spine fusion surgery, including biologics. The Company's product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS. The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide maximum visualization and are designed to enable safe and reproducible outcomes for the surgeon and the patient. The platform includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and a variety of specialized implants. The Company's primary business model is to loan its MAS systems to surgeons and hospitals that purchase implants, biologics and disposables for use in individual procedures. In addition, for larger customers, the Company's proprietary nerve monitoring systems, MaXcess and surgical instrument sets are placed with hospitals for an extended period at no up-front cost to them. The Company also offers a range of bone allograft in patented saline packaging, disposables and spine implants, which include its branded CoRoent products and fixation devices such as rods, plates and screws. Implants, biologics and disposables are shipped from the Company's inventories. The Company sells an immaterial quantity of MAS instrument sets, MaXcess and nerve monitoring systems to hospitals. Its spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable access to the spine and to perform restoration and fusion procedures in a minimally disruptive fashion. In the United States, it currently sells its products through a combination of exclusive independent sales agencies and directly-employed sales shareowners. The Company has approximately 230 issued U.S. patents, 165 foreign national patents, and 284 pending patent applications. The Company's competitors are Medtronic Sofamor Danek (Medtronic), DePuy/Synthes, a Johnson & Johnson company, Stryker Spine, Globus Medical, Biomet Spine, and Zimmer Spine. It also faces competition from physician owned distributorships (PODs), which are medical device distributors that are owned, directly or indirectly, by physicians. The Company's products,medical devices and tissues subject to regulation by the FDA and other regulatory bodies.

Top Ranked Articles about NuVasive Inc

Insiders Load Up on NuVasive as Price Tumbles 3 company insiders collectively purchase 26,172 shares
Multiple insiders of NuVasive (NUVA) purchased a total of 26,172 insider shares this week. Read more...

Ratios

vs
industry
vs
history
PE Ratio 130.72
NUVA's PE Ratio is ranked lower than
94% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. NUVA: 130.72 )
Ranked among companies with meaningful PE Ratio only.
NUVA' s PE Ratio Range Over the Past 10 Years
Min: 11.39  Med: 87.24 Max: 387.67
Current: 130.72
11.39
387.67
Forward PE Ratio 36.50
NUVA's Forward PE Ratio is ranked lower than
75% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. NUVA: 36.50 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 130.72
NUVA's PE Ratio without NRI is ranked lower than
94% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. NUVA: 130.72 )
Ranked among companies with meaningful PE Ratio without NRI only.
NUVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.39  Med: 87.24 Max: 387.67
Current: 130.72
11.39
387.67
PB Ratio 5.41
NUVA's PB Ratio is ranked lower than
73% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. NUVA: 5.41 )
Ranked among companies with meaningful PB Ratio only.
NUVA' s PB Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.61 Max: 10.89
Current: 5.41
0.98
10.89
PS Ratio 4.13
NUVA's PS Ratio is ranked lower than
61% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. NUVA: 4.13 )
Ranked among companies with meaningful PS Ratio only.
NUVA' s PS Ratio Range Over the Past 10 Years
Min: 0.85  Med: 3.17 Max: 10.54
Current: 4.13
0.85
10.54
Price-to-Free-Cash-Flow 60.80
NUVA's Price-to-Free-Cash-Flow is ranked lower than
82% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. NUVA: 60.80 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NUVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.97  Med: 49.75 Max: 670.85
Current: 60.8
6.97
670.85
Price-to-Operating-Cash-Flow 24.81
NUVA's Price-to-Operating-Cash-Flow is ranked lower than
64% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. NUVA: 24.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NUVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.76  Med: 18.47 Max: 365.19
Current: 24.81
4.76
365.19
EV-to-EBIT 40.35
NUVA's EV-to-EBIT is ranked lower than
73% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. NUVA: 40.35 )
Ranked among companies with meaningful EV-to-EBIT only.
NUVA' s EV-to-EBIT Range Over the Past 10 Years
Min: -166  Med: 23.8 Max: 559.6
Current: 40.35
-166
559.6
EV-to-EBITDA 20.43
NUVA's EV-to-EBITDA is ranked lower than
64% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. NUVA: 20.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
NUVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -320.9  Med: 15.2 Max: 4339.7
Current: 20.43
-320.9
4339.7
Shiller PE Ratio 874.58
NUVA's Shiller PE Ratio is ranked lower than
96% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 49.62 vs. NUVA: 874.58 )
Ranked among companies with meaningful Shiller PE Ratio only.
NUVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 705.56  Med: 832.86 Max: 963.14
Current: 874.58
705.56
963.14
Current Ratio 2.37
NUVA's Current Ratio is ranked lower than
51% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. NUVA: 2.37 )
Ranked among companies with meaningful Current Ratio only.
NUVA' s Current Ratio Range Over the Past 10 Years
Min: 1.7  Med: 3.81 Max: 8.37
Current: 2.37
1.7
8.37
Quick Ratio 1.51
NUVA's Quick Ratio is ranked lower than
56% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. NUVA: 1.51 )
Ranked among companies with meaningful Quick Ratio only.
NUVA' s Quick Ratio Range Over the Past 10 Years
Min: 1.25  Med: 2.79 Max: 7.36
Current: 1.51
1.25
7.36
Days Inventory 301.55
NUVA's Days Inventory is ranked lower than
83% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. NUVA: 301.55 )
Ranked among companies with meaningful Days Inventory only.
NUVA' s Days Inventory Range Over the Past 10 Years
Min: 266.24  Med: 334.46 Max: 491.78
Current: 301.55
266.24
491.78
Days Sales Outstanding 65.10
NUVA's Days Sales Outstanding is ranked higher than
52% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. NUVA: 65.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
NUVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 52.35  Med: 58.06 Max: 75.34
Current: 65.1
52.35
75.34
Days Payable 13.87
NUVA's Days Payable is ranked lower than
92% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. NUVA: 13.87 )
Ranked among companies with meaningful Days Payable only.
NUVA' s Days Payable Range Over the Past 10 Years
Min: 12.75  Med: 27.32 Max: 63.36
Current: 13.87
12.75
63.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.90
NUVA's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. NUVA: -3.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NUVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -215.4  Med: -5 Max: -3.8
Current: -3.9
-215.4
-3.8

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 4.32
NUVA's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
76% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. NUVA: 4.32 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NUVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.2  Med: 2.51 Max: 18.72
Current: 4.32
1.2
18.72
Price-to-Median-PS-Value 1.30
NUVA's Price-to-Median-PS-Value is ranked lower than
70% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. NUVA: 1.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NUVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.3  Med: 1.04 Max: 2.8
Current: 1.3
0.3
2.8
Earnings Yield (Greenblatt) % 2.48
NUVA's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. NUVA: 2.48 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NUVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 2.5 Max: 6.8
Current: 2.48
0.2
6.8

More Statistics

Revenue (TTM) (Mil) $962.1
EPS (TTM) $ 0.57
Beta1.01
Short Percentage of Float11.82%
52-Week Range $38.46 - 75.10
Shares Outstanding (Mil)50.60

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,068 1,157 1,244
EPS ($) 2.02 2.48 2.81
EPS without NRI ($) 2.02 2.48 2.81
EPS Growth Rate
(Future 3Y To 5Y Estimate)
19.10%
Dividends per Share ($)
» More Articles for NUVA

Headlines

Articles On GuruFocus.com
Insiders Load Up on NuVasive as Price Tumbles Nov 03 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Most-Bought Small Cap Stocks During 4th Quarter Mar 28 2016 
Weekly CEO Buys Highlight: BRKR, GAIN, LUB, NUVA, FGP Jun 21 2015 
Weekly CEO Buys Highlight: TPC, GBDC, NUVA, TEGP, JOY Jun 14 2015 
Weekly CEO Buys Highlight: TPC, NUVA, PHII, GBDC, ARO Jun 10 2015 
Weekly CEO Buys Highlight: NUVA, HK, BKFS, PODD, CLF Jun 02 2015 
Guru Fisher Cuts NUVA - Medical Insurance Resists NuVasive Procedure Apr 11 2013 
NuVasive Inc. (NUVA) President and COO Keith Valentine sells 2,015 Shares Jan 25 2011 
Weekly Guru Bargains Highlights: ASIA , SAY , VRX , AMLN , NUVA Jan 09 2011 

More From Other Websites
NUVASIVE INC Financials Feb 15 2017
Bets on financials, pharma power U.S. hedge funds' strong start to year Feb 14 2017
NuVasive, Inc. :NUVA-US: Earnings Analysis: 2016 By the Numbers : February 14, 2017 Feb 14 2017
NuVasive, Inc. :NUVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 13, 2017 Feb 13 2017
NuVasive (NUVA) Beats Q4 Earnings, Revenues; Guides 2017 Feb 10 2017
Edited Transcript of NUVA earnings conference call or presentation 9-Feb-17 9:30pm GMT Feb 09 2017
NuVasive tops Street 4Q forecasts Feb 09 2017
NuVasive tops Street 4Q forecasts Feb 09 2017
NUVASIVE INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Feb 09 2017
NuVasive Reports Fourth Quarter And Full Year 2016 Financial Results Feb 09 2017
Manufacturer hiring 200+ at Dayton-area facility Feb 09 2017
Q4 2016 NuVasive Inc Earnings Release - After Market Close Feb 09 2017
Why NuVasive (NUVA) Might Surprise This Earnings Season Feb 07 2017
NuVasive To Present At Leerink Partners 6th Annual Global Healthcare Conference 2017 Feb 06 2017
NuVasive Announces Conference Call and Webcast of Fourth Quarter 2016 Results Jan 13 2017
NuVasive at 52-Week High on Preliminary Results, MHLW Nod Jan 12 2017
ETFs with exposure to NuVasive, Inc. : January 9, 2017 Jan 09 2017
NuVasive Announces Select Preliminary Unaudited Full Year 2016 Financial Results and 2017 Outlook Jan 09 2017
NUVASIVE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 09 2017
NuVasive to Present at the 35th Annual J.P. Morgan Healthcare Conference Jan 04 2017
NuVasive (NUVA) Wins MHLW Approval for XLIF Device Suite Dec 30 2016
NuVasive to Resume XLIF Procedures in Japan in First Quarter 2017 Dec 29 2016
NuVasive to Resume XLIF Procedures in Japan in First Quarter 2017 Dec 29 2016
NuVasive to Showcase Integrated Global Alignment for the Cervical Spine at CSRS 2016 Dec 01 2016
NuVasive Secures Magnetic Resonance (MR) FDA Conditional Clearance for MAGEC System Oct 27 2016
NuVasive First-to-Market With New Spine Innovations Featured at NASS 2016 Oct 25 2016
NuVasive Reports Third Quarter 2016 Financial Results Oct 25 2016
NuVasive Announces Date Change for Conference Call and Webcast of Third Quarter 2016 Results Oct 18 2016
NuVasive Appoints Joan Stafslien as Executive Vice President, General Counsel Oct 03 2016
NuVasive Announces Conference Call and Webcast of Third Quarter 2016 Results Sep 26 2016
NuVasive Receives FDA 510(k) Clearance Reinforcing Comprehensive Portfolio Supporting Pediatric,... Sep 19 2016
NuVasive Names Jason M. Hannon President and Chief Operating Officer; Patrick S. Miles Assumes Role... Sep 12 2016
NuVasive to Participate in Investor Events in September 2016 Sep 02 2016
NuVasive Secures CMS Add-On Payment for Innovative MAGEC System Aug 04 2016
Michael D. O'Halleran and Patrick S. Miles Elected to NuVasive Board of Directors Aug 01 2016
NuVasive Reports Second Quarter 2016 Financial Results Jul 26 2016
NuVasive to Feature Industry-Leading Portfolio at 23rd International Meeting on Advanced Spine... Jul 12 2016
NuVasive Completes Acquistion of Biotronic NeuroNetwork Jul 05 2016
NuVasive Announces Conference Call and Webcast of Second Quarter 2016 Results Jun 29 2016
NuVasive to Acquire Biotronic NeuroNetwork Jun 06 2016
NuVasive to Participate in Investor Events in June 2016 May 31 2016
NuVasive Launches Next Generation Biologics Technology May 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)